Basic Information
Prolium Bioscience is a clinical-stage company developing PRO-203, a potential best-in-class bispecific CD20xCD3 antibody for systemic sclerosis and other severe autoimmune diseases. Prolium was founded and supported by RTW Investments and has assembled an experienced team in the development of therapeutic drugs for autoimmune diseases.
Prolium Bioscience, Inc.
NewYork,NewYork,United States of America
unclear
January 01, 2025
--
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios